Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

HRTX Mar 2022 11.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
3.39000.0000 (0.00%)
At close: 01:31PM EST
Advertisement
Full screen
Previous Close3.3900
Open3.3900
Bid2.1500
Ask3.3000
Strike11.00
Expire Date2022-03-18
Day's Range3.3900 - 3.3900
Contract RangeN/A
Volume8
Open Interest66
  • GuruFocus.com

    Newbridge Financial Services Group, Inc. Buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, ...

    Investment company Newbridge Financial Services Group, Inc. (Current Portfolio) buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, Microsoft Corp, Tesla Inc, sells NIO Inc, Lemonade Inc, Alibaba Group Holding, Carnival Corp, Blackstone Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Newbridge Financial Services Group, Inc..

  • GuruFocus.com

    Private Asset Management Inc Buys ASML Holding NV, Public Storage, Palantir Technologies Inc, ...

    San Diego, CA, based Investment company Private Asset Management Inc (Current Portfolio) buys ASML Holding NV, Public Storage, Palantir Technologies Inc, Kimco Realty Corp, Vanguard Dividend Appreciation FTF, sells Alibaba Group Holding, Heron Therapeutics Inc, The Energy Select Sector SPDR Fund, Danaher Corp, Dominion Energy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Private Asset Management Inc.

  • Motley Fool

    Why Heron Therapeutics Shares Rose Nearly 15% This Week

    The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.

Advertisement
Advertisement